 |
|||||||||
 |
|||||||||
Toronto, ON – TheNewswire – July 5, 2023 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company“), (TSXV:VPT) (OTC:VPTDF) is pleased to announce that a VMS+ product has been purchased by and is fully operstional in the Deutsches Herzzentrum der Charité (DHZC), German Heart Center, in Berlin, Germany.
Prof. Felix Berger, Director of the Clinic for Congenital Heart Disease – Pediatric Cardiology at DHZC stated, “VMS+ not only gives us a very precise spatial view of complex congenital malformations at any time, but it also provides us with important data on the function of the heart muscle. This allows us to plan therapy even more precisely, check it at any time and adjust it if necessary.”
The DHZC is the university heart center of Charité– Universitätsmedizin Berlin which is the largest heart center in Germany for the treatment of all cardiovascular diseases in patients of all ages. The Charité is one of Germany’s most research-intensive medical institutions and was ranked this year as the 7th best hospital in the world and the best in Europe by Newsweek (https://www.newsweek.com/rankings/worlds-best-hospitals-2023). The DHZC’s departments for Congenital Heart Disease – Pediatric Cardiology and Congenital and Pediatric Heart Surgery are among the leading institutions in Europe for the diagnosis and therapy of congenital and acquired heart disease (CHD). In 2021, the unit treated 1,005 statutory and 2,300 ambulatory CHD children. These numbers are continuously growing with the patients coming from Eastern Europe and neighbouring countries. Approximately 6,000 children are born in Germany every year with heart defects that require treatment and lifelong monitoring. The German Heart center is the central point of contact for advice, diagnostics, and therapy for the life of patients with CHD.
The VMS+ will be an asset to the hospital’s pediatric cardiology led by Prof. Dr. med. Felix Berger, a world-renowned pediatric cardiologist. The innovative product was purchased in order to improve efficacy and patient management in the CHD department. The VMS+ offers an accessible and timely cardiac diagnostic alternative to cMRI. The VMS+ with Knowledge-Based Reconstruction (KBR™) produces metrics that are more accurate and reliable compared to other standard ultrasound measurement techniques. This exciting new site will give the VMS+ larger visibility in the European market. Ventripoint strives to advance care for cardiovascular diseases for everyone and especially for children.
The DHZC’s purchase was enabled by Ventripoint’s partner in Europe, Angiopro GmbH, a leading German-based distributor.
About Ventripoint Diagnostics Ltd.
Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint’s VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint’s products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.
www.ventripoint.com
For further information, please contact:
Jonathan Robinson CFA
(416) 669-1001
About the German Heart Center Berlin
As of January 1, 2023, Charité – Universitätsmedizin Berlin and Deutsches Herzzentrum Berlin – Stiftung des bürgerlichen Rechts (DHZB) merge their cardiac medical facilities to form Deutsches Herzzentrum der Charité (DHZC). The DHZC is located at the three clinical campuses of Charité at Campus Virchow-Klinikum, Campus Charité Mitte and Campus Benjamin Franklin. It comprises a total of eight clinics and institutes with about 2,500 employees and has about 470 beds. This formation creates one of the largest cardiac centers in Germany for the treatment of all cardiovascular diseases in patients of all ages. Website: https://www.dhzb.de
About Angiopro GmbH
Angiopro is a classic distributor company with headquarters in Speyer, Rhineland-Palatinate. The company portfolio includes the distribution of vascular medical devices as well as the world’s leading software in patient screening before and after cardiovascular interventions. Website: www.angiopro.de
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.
Forward Looking Statements
This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words “expect”, “anticipate”, “continue”, “estimate”, “objective”, “ongoing”, “may”, “will”, “project”, “should”, “believe”, “plans”, “intends” and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.
Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company’s most recent annual management’s discussion and analysis that is available on the Company’s profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.
Copyright (c) 2023 TheNewswire – All rights reserved.
